Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: Final long-term efficacy results on motor complications from the GLORIA registry
Objective: To evaluate the effect of levodopa-carbidopa intestinal gel (LCIG, designated in the United States as carbidopa-levodopa enteral suspension) on motor fluctuations and dyskinesia in…Medication use patterns vary across expert Parkinson’s disease clinics
Objective: This analysis aims to describe and quantify the medication patterns for patients with Parkinson's disease (PD) managed in expert clinics. Background: Antiparkinson medication use…Association between clinical features and pre- and post-synaptic dopaminergic dysfunction in multiple system atrophy: [18F]-FP-CIT PET and [18F]-FDG PET analyses
Objective: To investigate the correlation between clinical features and pre- and post-synaptic dopaminergic dysfunction in patients with multiple system atrophy (MSA). Background: Multiple system atrophy…Influence of levodopa on functional brain connectivity in Parkinson’s disease
Objective: To evaluate how functional connectivity estimated by resting-state functional magnetic resonance imaging (rs-fMRI) is influenced by levodopa and associated with clinical symptoms in Parkinson's…Impact of chronic LD treatment on metabolism, blood flow and blood-brain barrier permeability in the 6-OHDA rat model
Objective: To determine the effects of chronic LD treatment and induction of dyskinesias on cerebral metabolism, blood flow and blood-brain barrier permeability in 6-OHDA rat…Telemedicine facilitates efficient and safe home titration of levodopa/carbidopa intestinal gel (LCIG) in patients with advanced Parkinson’s disease
Objective: To demonstrate feasibility of TM for LCIG home titration, evaluate resource use, and assess patient, neurologist and nurse satisfaction. Background: LCIG, is used for…Levodopa/carbidopa intestinal gel treatment in advanced Parkinson’s disease: A long-term observational study
Objective: To evaluate long-term efficacy, levodopa dose changes and complications in patients with advanced Parkinson's disease (PD) treated. Background: Administrated via percutaneous gastric gastrostomy to…Safety and tolerability of inhaled levodopa (CVT-301) administered to Parkinson’s disease patients with motor fluctuations
Objective: Two Phase 2 studies were conducted to evaluate the safety profile of inhaled CVT-301 administered to Parkinson's disease (PD) patients with motor fluctuations. Background:…Impact of comorbidities and compliance initiatives in management of patients with early Parkinson’s disease
Objective: To evaluate the impact of comorbidities and compliance iniciatives on treatment efficacy in patients with Parkinson's disease. Methods: In the year 2014 we included…The kinase Fyn mediates levodopa induced dyskinesias in Parkinson´s disease
Objective: To pharmacologically manipulate the kinase Fyn as a novel target to control levodopa induced dyskinesias. Background: The management of levodopa induced dyskinesias (LID) in…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.